Fig 1.
Flow diagram giving details of the enrolled individuals, and the procedure for propensity score matching.
Table 1.
Baseline clinical characteristics of the cohort.
Table 2.
Risks of herpes zoster in statin users and non-statin users.
Fig 2.
Cumulative incidences of herpes zoster (%) according to the use of statins.
Kaplan–Meier curves showing cumulative incidences (%) of individuals suffering from herpes zoster. Red line indicating herpes zoster in statin users. Blue line depicting herpes zoster in non-statin users. The difference between statin users and non-statin users was significant (p < .0001 by the log rank test).
Table 3.
Dose response relationship between duration of statin use and incidence of herpes zoster.